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Background: Treatment of low-dose aspirin (LDA)-induced small-bowel injury has not been established.
Polaprezinc, a chelate of zinc and L-carnosine, may be efficacious for such injury. We conducted a pilot randomized
controlled study to investigate whether polaprezinc is effective against LDA-induced small-bowel injuries.
Methods: Consecutive patients under long-term (>3 months) LDA treatment and who agreed to participate in our
study underwent initial capsule endoscopy (CE). Patients with LDA-induced small-bowel injury apparent upon initial
CE (n = 20) were randomized into a polaprezinc (150 mg/day for 4 weeks) group and a control (no polaprezinc
treatment) group. All underwent follow-up CE after 4 weeks. Changes in the number and characteristics of small-
bowel mucosal injuries were compared within and between the two groups.
Results: The median number of reddened lesions and erosions/ulcers upon follow-up CE in the polaprezinc group
significantly decreased (P < 0.05). However, there was no significant difference in the median number of reddened
lesions and erosions/ulcers upon follow-up CE in the control group.
Conclusions: Co-administration of polaprezinc may be effective against small-bowel mucosal injury associated with
long-term LDA therapy.
Trial registration: UMIN Clinical Trials Registry UMIN000003687.
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Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), is
one of the most-prescribed medications worldwide, and
low-dose aspirin (LDA), usually defined as 75-325 mg daily,
is commonly used for primary and secondary prevention of
cardiovascular events and stroke [1-3]. However, the use of
NSAIDs, including aspirin, is associated with risk of upper
gastrointestinal mucosal damage, manifesting as peptic
ulcer and/or bleeding [4-7]. NSAIDs, including aspirin, can
also induce small-bowel injury and, now that small-bowel
endoscopy is available for detection of small-bowel lesions,* Correspondence: oka4683@hiroshima-u.ac.jp
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reproduction in any medium, provided the orhave become a matter of interest to gastroenterologists
[8-10].
Neither protection against nor treatment of LDA-
induced small-bowel mucosal injuries has been established.
In Japan, polaprezinc is commonly used for the treatment
of gastric ulcer. Polaprezinc is a chelate compound
consisting of zinc and L-carnosine that is thought to func-
tion in protecting intercellular tight junctions [11,12], as an
anti-oxidant [13], in preventing apoptosis [14-16], and in
reducing inflammation [17]. Omatsu et al. [14] speculated
that polaprezinc protects rat intestinal epithelial (RIE-1)
cells from indomethacin-induced apoptosis via its reactive
oxygen species (ROS)-quenching effect. Mahmood et al.
[18] reported that zinc carnosine prevented the rise in gut
permeability caused by indomethacin in healthy volunteers,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Polaprezinc may have potential to protect against or
treat NSAID-induced small-bowel injury. Therefore, we
conducted a pilot randomized controlled study to assess




Consecutive patients undergoing upper gastrointestinal en-
doscopy or colonoscopy at Hiroshima University Hospital
and taking LDA between May 2010 and September 2011
were screened for inclusion in the study. These patients
were visiting our hospital for endoscopic treatment of
gastrointestinal tumor, follow-up endoscopic examination
after endoscopic treatment, treatment of gastrointestinal
bleeding outside the small intestine, or examination for
obscure gastrointestinal bleeding (OGIB). Inclusion criteria
were as follows: use of low-dose enteric-coated aspirin at
100 mg once daily for more than 3 months; no current use
of antibiotics; age ≥ 21years; an initial CE examination. Ex-
clusion criteria were as follows: use of NSAIDs other than
LDA; inflammatory bowel disease; digestion-absorption
disorder; polaprezinc treatment; use of other medicines for
gastritis, e.g., misoprostol or rebamipide, within the prior 6
months; use of antibiotics or thyroxine sodium; stenosis of
the gastrointestinal tract or severe adhesion; pregnancy or
nursing; severe ulcerative lesion(s) observed upon initial
CE, absence of small-bowel injury upon initial CE, and
failure of the CE capsule to reach the cecum. Twenty
patients in whom LDA-induced small-bowel injury was
identified upon initial CE, as described below, comprised
the final study group.
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the ethics
committee of Hiroshima University Hospital. All patients
screened for inclusion in the study were provided written
informed consent for participation. The trial is registered
with the UMIN Clinical Trials Registry as number
UMIN000003687.Figure 1 Capsule endoscopy images of small-bowel mucosal injuries
(depression with a white coating), (B) erosion (white spot surrounded by aStudy protocol
The 20 patients in whom LDA-induced small-bowel injury
was identified during the screening process were random-
ized into two groups: a polaprezinc group (n = 10) and a
control group (n = 10). For allocation of patients to the
study groups, we followed a block randomization scheme.
Patients were given their assignments in sealed envelopes
that had been shuffled previously. Patients in the
polaprezinc group were given polaprezinc at 150 mg daily
for 4 weeks, whereas patients in the control group were not
given polaprezinc during the 4-week period. All patients
continued LDA at 100 mg daily. Initial CE was defined as
CE performed at the time patients were first examined in
our department; follow-up CE was performed after 4 weeks
in both groups.
CE procedure and evaluation
The CE capsule (PillCam SB2; Given Imaging Ltd,
Yoqneam, Israel) was swallowed with a solution of
dimethicone after an overnight fast, without any other
preparation. Images were analyzed with Rapid Reader 6.5
software on a RAPID 6.0 workstation (both from Given Im-
aging). CE images were reviewed independently by two of
four experienced gastroenterologists (I.W., T.A., H.I., T.S.)
who were not provided any clinical information. If the
gastroenterologists’ findings differed, consensus was
reached through discussion.
NSAID-induced small-bowel injury is characterized by
multiple petechiae/red spots, denuded area, scars, mucosal
erosions, and ulcers with a round, irregular, or punched-out
appearance, or circumferential ulcers with stricture [19].
Such LDA-induced small-bowel injury was diagnosed at
the time of initial CE.
Small-bowel mucosal injuries were classified as either
erosion/ulcer or reddened lesion [20,21] as follows: erosion,
a white spot surrounded by a red halo; ulcer, depression
with a white coating; reddened lesion, reddish mucosal
change such as reddened folds, denuded area, and/or
petechiae (Figure 1); red spots were ignored in this study.
LDA-induced small-bowel injuries were defined as follows;induced by low-dose enteric-coated aspirin therapy. (A) Ulcer
red halo), (C) reddened lesion (reddish mucosal change).
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endoscopy, (2) use of LDA for more than 3 months, and
(3) exclusion of Crohn’s disease, intestinal tuberculosis and
any other small bowel disease.
We assessed the anatomic distribution of LDA-induced
small-bowel mucosal injuries upon initial CE according to
the following numerical formula based on capsule transit
time through the small intestine [22]: Lesion location, i.e.,
first, second, or third portion of the small bowel corre-
sponding to the percentage of total transit time, = (CE time
when lesion is found – CE time of first duodenal image)/
small bowel transit time.
To evaluate the effectiveness of polaprezinc, the number
of small-bowel injuries and CE score [23] were calculated
for each patient upon initial CE and upon follow-up CE.
Changes in the number of small-bowel injuries and the
difference in CE scores between initial CE and follow-up
CE were compared between the polaprezinc group and the
control group.
The CE score [23] was determined for small-bowel mu-
cosal inflammatory changes. The score was based on three
capsule endoscopy variables: villous appearance, ulceration,
and stenosis. Severity of the mucosal inflammatory changesTable 1 Characteristics of patients with small-bowel mucosal
polaprezinc treatment, i.e., control)
Characteristic Polap
Sex ratio (male/female)
Age (years); median (range) 7
Hemoglobin concentration (g/dL); median (range) 13










Median number of erosions/ulcers (range)
Median number of reddened lesions (range)
CE score
Median score (range) 1
CE score by category
Normal or clinically insignificant change (<135)
Mild change (≥135 and <790)
Moderate or severe change (≥790)
Number of patients are shown unless otherwise indicated.
*by Fisher’s exact test **by Wilcoxon test.
Abbreviations: CE, Capsule endoscopy; PPI, Proton pump inhibitor; N.S., Not significawas assessed in tertiles by dividing small-bowel capsule
transit time into three equal allotments. The total CE score
was taken as the highest tertile score plus the stenosis score.
The results were classified into three categories based on
the final numerical score: normal or clinically insignificant
change (total score <135), mild change (total score ≥135
but <789), and moderate to severe change (total score
≥790). This scoring system has been shown to be useful for
evaluating aspirin-associated small-bowel mucosal disease
activity and for objectively scoring the small-bowel inflam-
matory disease state [24].
Statistical analysis
Quantitative data are presented as median (range), and cat-
egorical data are presented as the number per group.
Between-group differences in sex ratio, anti-ulcer drug use,
indications for LDA therapy, and tertile CE scores were
analyzed by Fisher’s exact test. Within-group differences
between initial CE and follow-up CE in the number of
ulcers/erosions and reddened lesions and in CE scores were
analyzed by Wilcoxon signed-rank test. P < 0.05 was con-
sidered statistically significant. All analyses were performed
with JMP-J software.injuries per study group (polaprezinc treatment and no
rezinc (n = 10) Control (n = 10) P value
9/1 7/3 N.S.*
8.5 (64-82) 75.5 (62-86) N.S.**








2 (0-6) 2 (0-10) N.S.**
3 (0-7) 2 (0-7) N.S.**





Table 2 Number of small-bowel mucosal injuries and CE scores upon initial and follow-up CE in the polaprezinc
treatment group and non-polaprezinc (control) group
Initial CE Follow-up CE P value
Polaprezinc group (n = 10)
Median number of erosions/ulcers (range) 2 (0-6) 0 (0-4) 0.039*
Median number of reddened lesions (range) 3 (0-7) 1 (0-1) 0.003*
Median CE score (range) 180 (0-450) 0 (0-225) N.S.*
CE score by category
Normal or clinical insignificant change (<135) 3 6
Mild change (≥135 and <790) 7 4 N.S.**
Moderate or severe change (≥790) 0 0
Control group (n = 10)
Median number of erosions/ulcers (range) 2 (0-10) 0 (0-9) N.S.*
Median number of reddened lesions (range) 2 (0-7) 2 (0-7) N.S.*
Median CE score (range) 225 (0-225) 0 (0-450) N.S.*
CE score by category
Normal or clinically insignificant change (<135) 4 6
Mild change (≥135 and <790) 6 4 N.S.**
Moderate or severe change ((≥790) 0 0
Abbreviations: CE, Capsule endoscopy; N.S., Not significant.
*by Wilcoxon signed-rank test **by Fisher’s exact test.
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Figure 2 Anatomic distribution of small-bowel mucosal injuries observed by initial CE. Injuries are shown as one of three types for all
subjects. Location (first, second, or third portion of the small intestine) of each injury was determined according to time the injury was observed
in relation to total capsule transit time through the small intestine.
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Characteristics of the 20 patients randomized to the
polaprezinc group or control group are shown per group in
Table 1. There was no significant difference between the
two groups with regard to sex ratio, age, hemoglobin
concentration, indications for LDA, duration of LDA,
or anti-ulcer drug use. Neither was there a significant
difference between the two groups upon initial CE in the
number of erosions/ulcers and reddened lesions, total CE
score, or tertile CE scores.
The types and anatomic locations of the small-bowel
mucosal injuries observed upon initial CE are shown in
Figure 2. Reddened lesions and erosions were evenly
distributed throughout the small bowel, but ulcers tended
to be located in the third section of the small bowel.
The median number of erosions/ulcers identified upon
initial CE in the polaprezinc group was 2 (range 0-6), and
the median number of reddened lesions was 3 (range 0-7).
The median numbers in the control group were 2 (range 0-
10) and 2 (range 0-7), respectively. As shown in Table 2,
the median number of erosions/ulcers depicted upon
follow-up CE in the polaprezinc group decreased signifi-
cantly to 0 (range 0-4) (P = 0.039). In the control group,Figure 3 Changes in the numbers of small-bowel mucosal injuries (frothere was no significant difference in the median number
of erosions/ulcers upon follow-up CE. The median number
of reddened lesions in the polaprezinc group decreased sig-
nificantly to 1 (range 0-1) upon follow-up CE (P = 0.003),
but in the control group, there was no significant difference
in the median number of reddened lesions observed upon
follow-up CE. Change in the numbers of small-bowel
mucosal injuries from initial CE to follow-up CE in both
groups is diagrammed in Figure 3. In addition to the
median numbers of reddened lesions, erosions/ulcers, the
median number of total lesions (reddened lesions/erosions/
ulcers) decreased significantly in the polaprezinc group.
The changes in median CE score between initial CE and
follow-up CE did not differ between the two groups.
Discussion
NSAIDs, including aspirin, cause small-bowel injury
through cyclooxygenase (COX)-dependent and COX-
independent pathways [25]. NSAIDs inhibit mucosal
prostaglandin (PG) synthesis by inhibiting COX activity.
NSAIDs decrease mucosal endogenous PG, resulting in
reduction of intestinal mucus, microcirculatory distur-
bances accompanying abnormally increased intestinalm initial to follow-up capsule endoscopy).
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creased mucosal permeability. Bjarnason et al. [26]
proposed a “three hit” hypothesis independent of the
COX-pathway. NSAIDs solubilize phospholipids on the
mucosal surface, directly damaging epithelial mitochon-
dria. The mitochondrial damage leads to calcium efflux
and to induction of free radicals; disruption of intercellular
junctions occurs, and mucosal permeability increases in
the small intestine [27]. Mucosal injuries can be caused by
the penetration of bile acid, proteolytic enzymes, intestinal
bacteria, and/or toxins.
The reported incidence of LDA-induced small-bowel
injury is 20-61.5% among healthy volunteers using short-
term LDA [24,28-30], and the reported prevalence of LDA-
induced small-bowel injury is 42.1-100% specifically among
patients with OGIB using long-term LDA [19,24,31,32].
The actual overall clinical prevalence of adverse effects of
long-term aspirin on the small bowel in asymptomatic
patients remains undocumented.
Endo et al. reported that aspirin-associated small bowel
ulcers tended to be located in the distal part of the small
bowel [19]. In our patients, although there was no specific
anatomic distribution of reddened lesions and erosion,
ulcers were specifically found in the ileum upon initial CE,
albeit there were only three such cases.
The recommended treatment for small-bowel injury in
patients undergoing LDA therapy is withdrawal of the
aspirin. However, in the majority of patients, LDA is used
as an antiplatelet agent, and it cannot be discontinued due
to the increased risk of cardiovascular or cerebrovascular
morbidity and mortality. Prevention and healing regimens
for LDA-induced small-bowel injuries are needed. To date,
several investigations regarding prevention and healing
regimens for aspirin-induced small-bowel injury have been
reported. Watanabe et al. [32] reported that among patients
suffering from cerebral and cardiovascular disorders,
misoprostol was administered to those taking LDA for
3 months or more, and, after 8 weeks, CE revealed that red
spots as well as mucosal breaks were completely eliminated
in 57% of the patients. Unfortunately, there was a high inci-
dence of side effects, e.g., diarrhea, hepatic dysfunction, and
albuminuria, and misoprostol is generally contraindicated
for women who could be pregnant.
Endo et al. [31] randomized patients taking LDA for
3 months or more into two groups: one given 3-month
probiotic treatment (oral Lactobacillus casei) and the other
not given the 3-month probiotic treatment. CE at 3 months
showed that the number of reddened lesions and/or
mucosal breaks had decreased in the group given L. casei.
The study reported herein is the first randomized
controlled study of the effectiveness of polaorezinc on small
bowel injury identified by CE in chronic LDA users.
Although our study was small (20 patients), limited to a
single center, and without a placebo control group, themedian number of reddened lesions and erosions/ulcers in
those treated with polaprezinc decreased significantly,
suggesting that polaprezinc may be clinically effective
in treating LDA-induced small-bowel injuries. No
polaprezinc-based improvement in CE score was observed
in our patients, but this might be due to the small number
of ulcers among our study patients, to the fact that the
lesions were fairly small, with most being less than one-
quarter of the circumference of the small bowel, and to the
absence of stenosis.
Generally, small-bowel endoscopy, including CE and
DBE, is not performed except in OGIB cases or symptom-
atic cases. We are convinced that further studies are
warranted to determine which patients undergoing LDA
therapy should undergo endoscopic examination for small-
bowel lesions, which drugs are effective for such lesions,
and whether the same drugs can be used even to prevent
such lesions.
Conclusions
Co-administration of polaprezinc may be effective for
LDA-induced small-bowel injuries.
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